Utama Radar Cahaya Tbk. PT (RCCC)
IDX IDX Primary Summary
Utama Radar Cahaya Tbk. PT (RCCC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Utama Radar Cahaya Tbk. PT ever had a stock split?
Utama Radar Cahaya Tbk. PT Profile
| Biotechnology Industry | Healthcare Sector | Mr. Alvin Tjokrohadi CEO | IDX Exchange | ID1000170004 ISIN |
| ID Country | 100 Employees | - Last Dividend | 21 Jun 2024 Last Split | - IPO Date |
Overview
JW (Cayman) Therapeutics Co. Ltd positions itself at the forefront of the cell therapy industry, focusing on the battle against cancer within the People’s Republic of China. Established in 2016 and based in Shanghai, the company is deeply engaged in the clinical stage development, manufacturing, and commercialization of innovative anti-tumor drugs. It specializes in cell-based immunotherapies, particularly CAR-T treatments, which revolutionize cancer treatment by harnessing the body's immune cells. The firm's commitment to addressing a range of hematological cancers positions it as a key player in the field of oncological research and therapy.
Products and Services
The therapeutic offerings from JW (Cayman) Therapeutics Co. Ltd encompass a variety of advanced treatments targeting several forms of cancer, highlighting its dedication to leveraging cellular therapies for oncological diseases:
- Carteyva (relmacabtagene autoleucel)
This lead product candidate is an innovative anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy. It is specifically designed for treating a spectrum of hematological cancers, employing engineered T cells to identify and eliminate cancer cells expressing the CD19 antigen.
- JWCAR129
As part of the company's expanding portfolio, JWCAR129 is an autologous CAR-T therapy under development for tackling multiple myeloma. This condition, a type of blood cancer, has been notoriously difficult to treat, and JWCAR129 represents a promising advance in therapeutic options.
- JWATM204
This candidate is being developed as a TCR T-cell therapy for hepatocellular carcinoma (HCC), one of the most common forms of liver cancer. By utilizing T-cell receptor (TCR) technology, JWATM204 aims to direct the immune system specifically against cancerous cells in the liver, offering a novel treatment path for patients.
- JWATM203
Another pioneering therapy in the pipeline is JWATM203, an autologous T-cell receptor mimic T-cell therapy. It targets alpha-fetoprotein, a marker often present in hepatocellular carcinoma. This approach represents a targeted strategy to combat liver cancer, potentially improving outcomes for patients with this challenging diagnosis.
